Breaking: Does Myovant Sciences Ltd Have Any Gas After Today’s Big Increase?

Breaking: Does Myovant Sciences Ltd Have Any Gas After Today's Big Increase?

The stock of Myovant Sciences Ltd (NYSE:MYOV) is a huge mover today! The stock increased 7.98% or $0.88 on November 23, hitting $11.91. About 500,708 shares traded hands or 7.09% up from the average. Myovant Sciences Ltd (NYSE:MYOV) has risen 6.00% since October 25, 2016 and is uptrending. It has outperformed by 0.59% the S&P500.
The move comes after 9 months positive chart setup for the $705.80 million company. It was reported on Nov, 24 by Barchart.com. We have $12.74 PT which if reached, will make NYSE:MYOV worth $49.41 million more.

According to Zacks Investment Research, “Myovant Sciences Ltd. is a biopharmaceutical company. It focused on developing and commercializing therapies for women’s health diseases and other endocrine-related disorders, including advanced prostate cancer. The company’s product candidate consists of relugolix which are in clinical trial, an oral once-daily small molecule that acts as a gonadotropin-releasing hormone receptor antagonist. Myovant Sciences Ltd. is based in Hamilton, Bermuda.”

More notable recent Myovant Sciences Ltd (NYSE:MYOV) news were published by: Prnewswire.com which released: “Myovant Sciences Appoints Terrie Curran to Board of Directors” on November 16, 2016, also Prnewswire.com with their article: “Myovant Sciences Ltd. Announces Pricing of Initial Public Offering” published on October 27, 2016, Prnewswire.com published: “Roivant Sciences and Takeda Launch Myovant Sciences to Develop Innovative …” on June 06, 2016. More interesting news about Myovant Sciences Ltd (NYSE:MYOV) were released by: Prnewswire.com and their article: “Myovant Sciences Announces Appointment of Board of Directors” published on October 12, 2016 as well as Marketwatch.com‘s news article titled: “Myovant Sciences started at outperform at RW Baird” with publication date: February 01, 2001.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Leave a Comment